| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Caspase
Boc-Asp(OMe)-fluoromethyl ketone is a broad-range caspase inhibitor that targets multiple caspases involved in the apoptotic pathway. The compound is cell-permeable. It inhibits Fas-mediated phagocytosis and oxidative rupture inhibition but does not affect the chemotactic activity of IL-8. By inhibiting caspases, the compound blocks apoptosis and protects cells from Fas-induced and spontaneous cell death. |
|---|---|
| ln Vitro |
Polymorphonuclear leukocytes treated with Boc-Asp(OME)-Fluoromethyl Keton (100 μM; 30 minutes) are protected against both Fas-induced and spontaneous apoptosis (−CH-11)[1]. LDH release is considerably increased by Boc-Asp(OME)-Fluoromethyl Keton (20 μM; 5 hours; J774.1/JA-4 cells)[2].
In vitro studies demonstrate that Boc-Asp(OMe)-FMK (100 μM; 30 minutes) protects polymorphonuclear leukocytes against both Fas-induced and spontaneous apoptosis. The compound is a broad-range caspase inhibitor. It inhibits Fas-mediated phagocytosis and oxidative rupture inhibition but does not affect the chemotactic activity of IL-8. The compound is cell-permeable. |
| ln Vivo |
No detailed in vivo activity data has been published for Boc-Asp(OMe)-fluoromethyl ketone. The compound has been primarily characterized in vitro as a research tool for studying apoptosis and caspase function. Its ability to inhibit Fas-mediated apoptosis and protect cells from cell death suggests that it could have potential for in vivo applications in diseases involving apoptosis. Further studies would be needed to evaluate its efficacy in animal models.
|
| Enzyme Assay |
The caspase inhibitory activity of Boc-Asp(OMe)-FMK can be assessed using in vitro enzyme assays. In a typical assay, recombinant caspases are incubated with fluorogenic substrates and varying concentrations of Boc-Asp(OMe)-FMK. The cleavage of the substrates releases fluorescent products that are measured, and the IC50 is calculated. The compound's broad-range caspase inhibition can be confirmed using assays with different caspase isoforms.
|
| Cell Assay |
The cellular activity of Boc-Asp(OMe)-FMK is assessed using polymorphonuclear leukocytes or other cell types. Cells are treated with Boc-Asp(OMe)-FMK (100 μM; 30 minutes). Apoptosis is induced using Fas ligand or other apoptotic stimuli. Apoptosis is assessed by annexin V/propidium iodide staining, caspase activation assays, or DNA fragmentation analysis. The compound's ability to protect cells against Fas-induced and spontaneous apoptosis is measured.
|
| Animal Protocol |
No detailed in vivo animal model data has been published for Boc-Asp(OMe)-fluoromethyl ketone. The compound has been primarily characterized in vitro as a research tool for studying apoptosis. Future studies may involve the use of mouse models of diseases involving apoptosis to assess the in vivo efficacy of Boc-Asp(OMe)-FMK.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data has been published for Boc-Asp(OMe)-fluoromethyl ketone. The compound has a molecular weight of 263.26 g/mol and a molecular formula of C11H18FNO5. It is soluble in DMSO or dimethyl formamide. The compound has a purity of ≥95% (TLC). Further studies would be needed to characterize its absorption, distribution, metabolism, and excretion properties.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data has been published for Boc-Asp(OMe)-fluoromethyl ketone. As a broad-range caspase inhibitor, it may have on-target effects on apoptosis in normal tissues. Comprehensive toxicology studies would be required to evaluate its safety profile for potential therapeutic development. The compound is intended for research use only.
|
| References |
|
| Additional Infomation |
Boc-Asp(OMe)-fluoromethyl ketone (Boc-Asp(OMe)-FMK, CAS# 187389-53-3) is a broad-range cell-permeable caspase inhibitor. It protects against Fas-induced and spontaneous apoptosis. The compound inhibits Fas-mediated phagocytosis but does not affect IL-8 chemotactic activity. It has a molecular weight of 263.26 g/mol and a molecular formula of C11H18FNO5. The compound has a purity of ≥95% (TLC). It is soluble in DMSO or dimethyl formamide. The compound is used in apoptosis research.
|
| Molecular Formula |
C11H18FNO5
|
|---|---|
| Molecular Weight |
263.26272
|
| Exact Mass |
263.116
|
| CAS # |
187389-53-3
|
| PubChem CID |
9881695
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
383.5±37.0 °C at 760 mmHg
|
| Flash Point |
185.7±26.5 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.440
|
| LogP |
1.91
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
18
|
| Complexity |
324
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(OC(N[C@H](C(CF)=O)CC(OC)=O)=O)C
|
| InChi Key |
MXOOUCRHWJYCAL-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C11H18FNO5/c1-11(2,3)18-10(16)13-7(8(14)6-12)5-9(15)17-4/h7H,5-6H2,1-4H3,(H,13,16)/t7-/m0/s1
|
| Chemical Name |
methyl (3S)-5-fluoro-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxopentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (379.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7985 mL | 18.9926 mL | 37.9853 mL | |
| 5 mM | 0.7597 mL | 3.7985 mL | 7.5971 mL | |
| 10 mM | 0.3799 mL | 1.8993 mL | 3.7985 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
